Loading...
Dernières publications
-
Luce Barbat Du Closel, Nathalie Bonello-Palot, Yann Pereon, Andoni Echaniz-Laguna, Jean Philippe Camdessanche, et al.. Clinical and electrophysiological characteristics of women with X-linked Charcot-Marie-Tooth disease. European Journal of Neurology, 2023, 30 (10), pp.3265-3276. ⟨10.1111/ene.15937⟩. ⟨hal-04254200⟩
-
Joe-Elie Salem, Marie Bretagne, Baptiste Abbar, Sarah Leonard-Louis, Stéphane Ederhy, et al.. Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis. Cancer Discovery, 2023, 13 (5), pp.1100-1115. ⟨10.1158/2159-8290.CD-22-1180⟩. ⟨hal-04578810⟩
-
Corinna Preuße, Barbara Paesler, Christopher Nelke, Derya Cengiz, Thomas Müntefering, et al.. Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis. Acta Neuropathologica, 2022, 144 (2), pp.353-372. ⟨10.1007/s00401-022-02438-z⟩. ⟨hal-03830925⟩
-
Lee Nguyen, Marie Bretagne, Jennifer Arrondeau, Noel Zahr, Stephane Ederhy, et al.. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. Journal for Immunotherapy of Cancer, 2022, 10 (4), pp.e004699. ⟨10.1136/jitc-2022-004699⟩. ⟨hal-03832478⟩
-
Lee Nguyen, Marie Bretagne, Jennifer Arrondeau, Noel Zahr, Stephane Ederhy, et al.. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. Journal for Immunotherapy of Cancer, 2022, 10 (4), pp.e004699. ⟨10.1136/jitc-2022-004699⟩. ⟨hal-04002766⟩
-
Stéphane Ederhy, Perrine Devos, Bruno Pinna, Elisa Funck-Brentano, Baptiste Abbar, et al.. 8 F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography imaging for the diagnosis of immune checkpoint inhibitors associated myocarditis. Archives of cardiovascular diseases, 2022, ⟨10.1016/j.acvd.2021.12.001⟩. ⟨hal-03561783⟩
Chiffres clés
123
Publications avec texte intégral
Open Access
53 %
Mots clés
Anti-IgE IgG
Biomarkers
COVID-19
Myositis
Agalsidase
Auto-antibodies
Assisted communication devices
Prognosis
Anti-interleukin-6
Anti-drug antibodies
Myopathy
Active
Auto-immunité
Amyotrophic lateral sclerosis
Anti-agalsidase antibodies
Anticorps anti-agalsidase
Lysosomal storage diseases
Autoantibodies
Adolescence
Fabry disease
Humans
Interstitial lung disease
Sphingosine-1-phosphate
Multidisciplinarity
Myositis and muscle disease
AAV humoral immunity
AAV vector
Antiphospholipid syndrome
Myocarditis
Aldosterone
Interferon
Outcome measures
Anti‐mitochondrial antibodies
Acute Kidney Injury/epidemiology/etiology
Systems biology
AAV antibody
Inflammation
Inflammatory myopathy
Autoantibody
Immune checkpoint inhibitors
Gene therapy
B-lymphocyte
Male
Adult
AAV
Dependovirus/genetics/immunology
Polymyositis
Adeno-associated vector
IMNM
Antibody responses
Antisynthétase
Anti-Mi2
Biopsy
AAV vectors
Adverse drug reactions
Anémie hémolytique
Auto‐antibodies
Anti-synthetase syndrome
Pharmacology
DM
Female
Antisynthetase syndrome
Biomarker
Anticorps spécifique des myosites
Adjudication
Acid-alpha-glucosidase
Adeno-associated virus
Abnormal movement
Aldostérone
B cell homeostasis
Inclusion body myositis
Analyses multidimensionnelles
Arthritis
Cytokines
Deep immune profiling
Mass cytometry
Animals
Autoimmune diseases
Dermatomyositis
Immunotherapy
Idiopathic inflammatory myopathies
Aged
Biomarqueurs
Amyotrophy
Middle Aged
Anti-MDA5 autoantibodies
Antisynthetase
Adeno-associated virus vector
Skeletal muscle
Inborn errors of metabolism
Cancer
IBM
Autoimmunity
Data integration
Bioelectrical impedance analysis
Machine learning
Cardio-oncology
Antibodies
Case reports
Muscle